YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
CONSHOHOCKEN, Pa., October 02, 2026--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on t…
2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, lead…
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
1 of Wall Street's Favorite Stocks with Impressive Fundamentals and 2 We Turn Down Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it's important to remain skepti…
Approval Nearly Doubles Exploration Footprint and Adds 212,500 Metres of Potential Drilling CapacityAcross Three Major Copper Trends VANCOUVER, BC / ACCESS Newswire / September 28, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF)…
CONSHOHOCKEN, Pa., September 25, 2026--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Mr. Sanchez is the Execut…
Cardinal Health CAH is increasingly using its multi-specialty management services organization (MSO) strategy to expand its presence in specialty care delivery. The company expects its MSO platforms to contribute to growth in fiscal 2027,…
Key Points Interested in Cencora, Inc.? Here are five stocks we like better. Cencora expects its specialty-focused strategy to drive growth through fiscal 2027, supported by demand in oncology and retina, expanded physician-services capabi…
Key Points Interested in Cencora, Inc.? Here are five stocks we like better. Specialty pharmaceuticals and MSOs are central to Cencora's growth strategy, with particular emphasis on retina and oncology practices. Management expects the MSO…
Cencora (COR) just combined a stronger fiscal third quarter, a higher full year adjusted EPS outlook, and a US$1b buyback with plans to brief investors at two New York healthcare conferences. Despite the upbeat earnings message, Cencora's…
Wall Street's major market averages finished mixed as Treasury yields rebounded, rekindling concerns about a deteriorating macroeconomic backdrop. The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500#source=url_first_level%3Amarket-ne…
On August 5, Cencora (NYSE:COR) reported results for its fiscal third quarter, which closed on June 30, and the headline numbers looked clean. Revenue rose 5.1% to $84.8 billion, adjusted earnings per share climbed 12.0% to $4.48, and mana…
Cencora Global Chief Data and Information Officer Pawan Verma spoke with WSJ Leadership Institute President Alan Murray at the WSJLI Technology Council Summit about how AI is being used in healthcare to speed access to treatment. Verma des…
A panel of CIOs from Indeed, New York Life and Cencora discuss the risks and advantages of enterprise AI, including operational efficiency, financial waste and the need to implement "control towers" for human oversight of consequential dec…
Choosing between a mature pharmaceutical giant and a speculative gene-editing pioneer requires a clear understanding of your personal risk tolerance. Do you prefer AbbVie (NYSE:ABBV) or CRISPR Therapeutics (NASDAQ:CRSP) in 2026? AbbVie is…
Coultreon Biopharma BV Nate Massari's business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis and Crohn's disease, will support the advancement of Coultreon's first-in-cla…
Choosing between Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires balancing the stability of a diversified pharmaceutical giant against the high-growth, high-margin profile of a specialized biotechnology pioneer. Amgen…
Cardinal Health CAH has gained 29.3% in the past four months, with investors increasingly recognizing the earnings contribution from its specialty-focused businesses and a broader portfolio of higher-margin growth assets. The Zacks Medical…
Investors choosing between Amgen (NASDAQ:AMGN) and Revolution Medicines (NASDAQ:RVMD) must weigh established cash flows against high-stakes clinical potential. Which of these healthcare players is the better addition to your portfolio toda…
Investors often face a choice between the stability of established giants and the high-stakes potential of clinical-stage innovators. Deciding between Amgen (NASDAQ:AMGN) and CRISPR Therapeutics (NASDAQ:CRSP) requires balancing immediate d…
The healthcare sector is shifting as legacy blockbusters face competition from low-cost generics while new chronic care treatments explode. Choosing between AbbVie Inc (NYSE:ABBV) and Novo Nordisk A/S (NYSE:NVO) requires weighing diversifi…
2 S&P 500 Stocks with Exciting Potential and 1 We Question The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are cr…
Should you bet on an established giant or a pipeline-driven innovator? This comparison examines Amgen (NASDAQ:AMGN) and Moderna (NASDAQ:MRNA) to see which stock is a better buy today. Amgen is a veteran in the drug manufacturing world, foc…
Cencora Inc_ HQ-by JHVEPhoto via iStock Conshohocken, Pennsylvania-based Cencora, Inc. (COR) sources and distributes pharmaceutical products in the United States and internationally. Valued at a market cap of $61.6 billion, the company dis…
Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at Cencora (NY…
Cencora COR is well poised for growth on the back of a robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern. This Zacks Rank #3 (Hold) company's shares have lost 0.2% in the year-to-date…
The pharmaceutical industry is shifting as legacy blockbusters lose patent protection. Investors must choose between AbbVie Inc (NYSE:ABBV) and Pfizer Inc (NYSE:PFE) as they navigate drug pricing reforms and evolving pipelines. AbbVie has…
It has been about a month since the last earnings report for Cencora (COR). Shares have added about 3.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is…
Cencora COR recently launched Cell and Gene Therapy (CGT) Enablement through its Accelerate Pharmacy Solutions business, offering support to health systems to evaluate, build and scale CGT programs. The new service is designed to improve o…
McKesson headquarters By JHVEPhoto Irving, Texas-based McKesson Corporation (MCK) distributes pharmaceuticals, medical-surgical supplies, and health and beauty care products principally in North America. Valued at a market cap of $107.4 bi…
Cencora (COR) drew investor attention after third quarter results showed adjusted earnings per share of US$4.48, up 12% year over year, along with a higher fiscal 2026 adjusted earnings outlook. Cencora's latest earnings beat and higher 20…
Cencora recently launched its Cell and Gene Therapy Enablement service through Accelerate Pharmacy Solutions to help health systems evaluate, build and scale advanced therapy programs, while also raising its fiscal 2026 adjusted earnings o…
On the September 2 episode of Mad Money, Jim Cramer called Cardinal Health, Inc. (NYSE:CAH) one of his "absolute favorites" and mentioned its growing exposure to specialty pharmaceuticals and higher-margin healthcare services. Cardinal's b…
Cencora COR raised its fiscal 2026 adjusted earnings outlook after third-quarter results showed faster profit growth across both healthcare solutions segments. Adjusted earnings per share rose 12% year over year to $4.48, topping the Zacks…
Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the "Artisan Global Opportunities Strategy". The letter can be downloaded here. Global equities rebounded sharply during the quart…
Generics continues to function as an important, relatively steady profit contributor for Cardinal Health's CAH Pharma business, even though its revenue impact can be uncertain due to changes in brand pricing, IRA-related adjustments and GL…